

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Purified anti-human CD34

RRID:AB_1731898

Type: Antibody

Proper Citation

BioLegend Cat# 343502, RRID:AB_1731898

Antibody Information

URL: http://antibodyregistry.org/AB_1731898

Proper Citation: BioLegend Cat# 343502, RRID:AB_1731898

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF??, ICC, IHC-P

Antibody Name: Purified anti-human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 581

Antibody ID: AB_1731898

Vendor: BioLegend

Catalog Number: 343502

Alternative Catalog Numbers: 343501

Record Creation Time: 20250820T053004+0000

Record Last Update: 20250820T214256+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD34.

No alerts have been found for Purified anti-human CD34.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. *Immunity*, 59(5), 1201.

Shen Y, et al. (2026) comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. *Cell stem cell*, 33(3), 421.

Gharibi B, et al. (2025) Post-gastrulation amnioids as a stem cell-derived model of human extra-embryonic development. *Cell*, 188(14), 3757.

Chen X, et al. (2024) METTL3-Mediated m6A Modification Regulates the Osteogenic Differentiation through LncRNA CUTALP in Periodontal Mesenchymal Stem Cells of Periodontitis Patients. *Stem cells international*, 2024, 3361794.

Roversi FM, et al. (2022) Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. *Cancer immunology, immunotherapy : CII*, 71(8), 1909.

Baskar R, et al. (2022) Integrating transcription-factor abundance with chromatin accessibility in human erythroid lineage commitment. *Cell reports methods*, 2(3).

Alpert A, et al. (2022) Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. *Cell systems*, 13(1), 71.

Henrick BM, et al. (2021) Bifidobacteria-mediated immune system imprinting early in life. *Cell*, 184(15), 3884.

Roussel M, et al. (2021) Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. *Cell reports. Medicine*, 2(6), 100291.

Rodriguez L, et al. (2020) Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. *Cell reports. Medicine*, 1(5), 100078.

Evrard M, et al. (2018) Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity*, 48(2), 364.

Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell*, 170(6), 1120.

Zhou W, et al. (2017) Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. *Cell stem cell*, 21(5), 591.

Sander J, et al. (2017) Cellular Differentiation of Human Monocytes Is Regulated by Time-Dependent Interleukin-4 Signaling and the Transcriptional Regulator NCOR2. *Immunity*, 47(6), 1051.